Company increases manufacturing capacity of U.S.-made drug to ensure uninterrupted supply for patients undergoing treatment amid industry shortage
San Francisco, CA (UroToday.com) Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, affirmed the full availability of ELIGARD® (leuprolide acetate) for injectable suspension in all doses for patients undergoing palliative treatment for advanced prostate cancer. The company confirmed the complete inventory of product supply and also announced a production increase in response to reports of a shortage in the United States for a different leuprolide acetate injection product used in the palliative treatment for advanced prostate cancer. Tolmar has a demonstrated record of providing a consistent supply of ELIGARD in the U.S. and globally across approximately 89 countries, with no shortages to date.
San Francisco, CA (UroToday.com) Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, affirmed the full availability of ELIGARD® (leuprolide acetate) for injectable suspension in all doses for patients undergoing palliative treatment for advanced prostate cancer. The company confirmed the complete inventory of product supply and also announced a production increase in response to reports of a shortage in the United States for a different leuprolide acetate injection product used in the palliative treatment for advanced prostate cancer. Tolmar has a demonstrated record of providing a consistent supply of ELIGARD in the U.S. and globally across approximately 89 countries, with no shortages to date.